Skip to main content
Equibles
ZNTL logo

ZNTL · Zentalis Pharmaceuticals, Inc. · Metrics

Track ZNTL — free

Use ZNTL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZNTL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.98 -0.09 (-4.35%) At close · Oct 27
Russell 2000 member Rebalance outlook locked
Market Cap
$142.99M
Shares
71.67M
Volume · Oct 27 1.72M Avg daily vol (3M) 1.18M

ZNTL metrics

75 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.98
Market cap
$142.99M

Price action

20 metrics
Price change (1W)
-10.0%
Price change (30D)
-20.4%
Price change (3M)
-54.1%
Price change (6M)
-51.3%
Price change (YTD)
+53.3%
Price change (1Y)
+21.1%
Trailing year
Price change (5Y)
-97.4%
52-week high
$6.61
52-week low
$1.28
Change from 52-week high
-68.7%
Change from 52-week low
+61.7%
Annualized volatility
129.5%
Annualized volatility (3M)
75.6%
Beta
2.1
RSI (14D)
31.4
Price vs SMA 50
-33.0%
Price vs SMA 200
-40.6%
Avg volume (3M)
1.17M
Relative volume
0.9
Average dollar volume
$3.82M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
71.67M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.1
reciprocal yield 94.8%
FCF yield
-84.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-92.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.9×
reciprocal yield 54.0%
EV / revenue historical average (5Y)
1.9×
reciprocal yield 54.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-02-27

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$153.37M
Net income (TTM)
−$139.54M
Trailing 12 months
Diluted EPS (TTM)
$-1.96
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.15
EBITDA per diluted share (TTM)
$-2.14
Net income per diluted share (TTM)
$-1.96
Operating cash flow per diluted share (TTM)
$-1.80
Free cash flow per diluted share (TTM)
$-1.80
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.63
Stock compensation per diluted share (TTM)
$0.20
Book value per share
$3.13

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-0.9%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-97.1%
Return on assets
-64.8%
Debt / equity
0.0
Current ratio
4.8
EBITDA (TTM)
−$152.75M
Free cash flow (TTM)
−$128.13M
Quick ratio
4.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$24.78M
Latest balance sheet
Cash & equivalents
$24.78M
Total assets
$215.33M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$128.09M
Capital expenditures (TTM)
$34,000
R&D (TTM)
$116.32M
SG&A (TTM)
—
Stock compensation (TTM)
$14.36M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
114
13F filer change QoQ
+12
Institutional ownership
67.0%
Conviction holders (share of 13F filers)
3.5%
Crowding (high-turnover and private-fund holders)
36.7%
Private-fund adviser ownership
33.5%
Active holders' share change QoQ
-2.2%
Holder tenure
10.5
Price vs estimated holder cost
-17.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.2%

Short interest

3 metrics
Short interest
8.4%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1725160 CUSIP 98943L107 13F (30d) 15 filings 15 filers Visit website Investor relations